British pharmaceutical giant AstraZeneca reported second-quarter results with profit exceeding market expectations, while maintaining its full-year and long-term outlook. Core earnings per share came in at $2.63, beating the consensus estimate of $2.48, and total revenue rose 5% to $15.38 billion. The company reiterated its forecast for full-year 2026 core EPS growth in the low teens and total revenue growth at a mid-to-high single-digit pace, and reaffirmed its target of achieving $80 billion in annual revenue by 2030.
AstraZeneca PLCQ2 profit beat and maintained guidance signal financial strength.